Back To Top

You have matched to 1 trial

Guest Profile:  No profile selected

Copy link
Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

Disitamab Vedotin Antibody-Drug Conjugate for Advanced HER2+, HER2 Low, or HER2 Ultralow Breast Cancer

A Phase 1b/2, Open-Label, Multicohort Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of disitamab vedotin antibody-drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+), HER2 low, or HER2 ultralow breast cancer. You must have received 1-3 prior lines of therapy for advanced disease. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Disitamab vedotin, by IV, every 2 weeks</li></ul>

What's being studied?


How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06966453' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.pfizer.com/science/drug-product-pipeline' target='_blank'>Pfizer: Disitamab vedotin</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Antibody-Drug Conjugates</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.pfizerclinicaltrials.com/nct06966453-breast-cancer-trial' target='_blank'>Advanced breast cancer clinical trial NCT06966453 | Pfizer</a> </li></ul>
1

Disitamab Vedotin Antibody-Drug Conjugate for Advanced HER2+, HER2 Low, or HER2 Ultralow Breast Cancer

A Phase 1b/2, Open-Label, Multicohort Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Icon

Nearest Location:
27 miles
Stanford Health Care, Investigational Drug Service
Stanford, CA

Icon

Visits:
Every 2 weeks

Icon

ClinicalTrials.gov: NCT06966453

Icon

Phase I-II

HELP GUIDE